These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9621137)

  • 1. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+ T lymphocytes.
    Zouboulis CC; Schmuth M; Doepfmer S; Dippel E; Orfanos CE
    Dermatology; 1998; 196(3):305-8. PubMed ID: 9621137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.
    Shiue LH; Couturier J; Lewis DE; Wei C; Ni X; Duvic M
    Photodermatol Photoimmunol Photomed; 2015 Jul; 31(4):184-94. PubMed ID: 25772268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal modulation of circulating CD4+CD25+bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients.
    Quaglino P; Comessatti A; Ponti R; Peroni A; Mola F; Fierro MT; Savoia P; Novelli M; Bernengo MG
    Int J Immunopathol Pharmacol; 2009; 22(2):353-62. PubMed ID: 19505389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.
    Atta M; Papanicolaou N; Tsirigotis P
    Transfus Apher Sci; 2012 Apr; 46(2):195-202. PubMed ID: 22067605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
    Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
    Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.
    Prinz B; Behrens W; Hölzle E; Plewig G
    Arch Dermatol Res; 1995; 287(7):621-6. PubMed ID: 8534123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
    Ferenczi K; Yawalkar N; Jones D; Kupper TS
    Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
    Bisaccia E; Vonderheid EC; Geskin L
    Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.
    Knobler R; Duvic M; Querfeld C; Straus D; Horwitz S; Zain J; Foss F; Kuzel T; Campbell K; Geskin L
    Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):250-7. PubMed ID: 22971190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD209
    Ni X; Austin M; Langridge T; Bojaxhi P; Bijani P; Wang X; Duvic M
    Photodermatol Photoimmunol Photomed; 2020 Jul; 36(4):290-298. PubMed ID: 32187738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
    Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
    Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T Cells in Chronic Graft-Versus-Host Disease After Extracorporeal Photopheresis: Correlation With Skin and Global Organ Responses, and Ability to Taper Steroids.
    Denney HA; Whittle RJ; Lai J; Jacques RM; Taylor PC
    Transplantation; 2017 Jan; 101(1):204-211. PubMed ID: 27007227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy.
    Macheiner W; Jantschitsch C; Graninger W; Pálóczy K; Bálint G; Marschalkó M; Kainberger F; Breier F; Knobler RM
    J Am Acad Dermatol; 2003 Feb; 48(2):220-6. PubMed ID: 12582392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+CD25+ lymphocyte subsets in chronic graft versus host disease patients undergoing extracorporeal photochemotherapy.
    Rubegni P; Sbano P; Cevenini G; Perari MG; Marotta G; Risulo M; Carcagnì MR; D' Ascenzo G; De Aloe G; Fimiani M
    Int J Immunopathol Pharmacol; 2007; 20(4):801-7. PubMed ID: 18179753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
    Girardi M; Carlson K; Huang X; Corman SL; Edmundson P; Schmier J; Kale HP; Raina R; Foss F
    J Dermatolog Treat; 2024 Dec; 35(1):2360568. PubMed ID: 38852942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
    Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
    J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
    Geskin L
    Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
    Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
    Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma.
    Tsai YC; Schlaepfer T; Ignatova D; Chang YT; Valaperti A; Amarov B; Blanchard G; Pehr K; Vonow-Eisenring M; Urosevic-Maiwald M; Hoetzenecker W; Pascolo S; Iselin C; Fassnacht C; Dimitriou F; Bobrowicz M; Guenova E
    Br J Dermatol; 2023 Oct; 189(5):603-611. PubMed ID: 37409661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis.
    Haley HR; Davis DA; Sams WM
    J Am Acad Dermatol; 1999 Nov; 41(5 Pt 2):880-3. PubMed ID: 10534677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.